Apoptosis Dysregulation in Lung Cancer: Therapeutic Resistance Mechanisms and Implications for Rural Healthcare Advancement in India
Keywords:
Apoptosis, lung cancer, MCL-1, BH3 mimetics, therapeutic resistance, telepathology, rural health, IndiaAbstract
Apoptosis is a fundamental mechanism for maintaining cellular homeostasis and eliminating damaged cells. In lung cancer, this tightly regulated process is frequently disrupted, enabling malignant cells to evade death and persist despite cytotoxic therapy. The two principal apoptotic pathways—intrinsic and extrinsic—are both implicated in this disruption. The intrinsic pathway is governed by the Bcl-2 family of proteins, which control mitochondrial outer membrane permeabilization and downstream caspase activation, while the extrinsic pathway is initiated by death receptors on the cell surface and proceeds through the death-inducing signaling complex. Mutations in key regulators such as TP53, overexpression of anti-apoptotic proteins (notably MCL-1 in non-small-cell lung cancer), and defects in death-receptor signaling collectively raise the apoptotic threshold and underlie resistance to chemotherapy, radiotherapy, and targeted agents. Emerging strategies—BH3 mimetics, MCL-1-selective inhibitors, pharmacological p53 reactivation, TRAIL-receptor agonists, and rational combinations—show promise but remain dependent on functional biomarkers of apoptotic dependence rather than static gene-expression data. This review synthesizes the mechanistic literature on apoptosis dysregulation in lung cancer and connects it to the rural Indian context, where rising incidence, biomass-fuel exposure, late-stage diagnosis, and limited access to specialized oncology require affordable, scalable, and decentralized strategies. We argue that apoptosis-targeted therapy will improve rural outcomes only if paired with upstream risk reduction, decentralized diagnostic pathways including telepathology, low-cost tumor-selective delivery platforms, and validation of functional biomarkers in resource-limited settings.
References
Acehan, D., Jiang, X., Morgan, D. G., Heuser, J. E., Wang, X., & Akey, C. W. (2002). Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation. Molecular Cell, 9(2), 423–432.
Ashkenazi, A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews Cancer, 2(6), 420–430.
Ashkenazi, A. (2008). Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews Drug Discovery, 7(12), 1001–1012.
Ashkenazi, A., & Dixit, V. M. (1998). Death receptors: Signaling and modulation. Science, 281(5381), 1305–1308.
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016). Tumor-suppressor functions of the TP53 pathway. Cold Spring Harbor Perspectives in Medicine, 6(5), a026062.
Bratton, S. B., & Salvesen, G. S. (2010). Regulation of the Apaf-1-caspase-9 apoptosome. Journal of Cell Science, 123(19), 3209–3214.
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., & Huang, D. C. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Cell Death and Differentiation, 12(1), 112–125.
Cory, S., & Adams, J. M. (2002). The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Reviews Cancer, 2(9), 647–656.
Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M., & Letai, A. (2007). BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell, 12(2), 171–185.
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013). On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene, 32(11), 1341–1350.
Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P., & Grandien, A. (1999). The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. The Journal of Experimental Medicine, 190(7), 1025–1032.
Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35(4), 495–516.
Gonzalvez, F., & Ashkenazi, A. (2010). New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene, 29(34), 4752–4765.
Green, D. R., & Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science, 305(5684), 626–629.
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999). BCL-2 family members and the mitochondria in apoptosis. Genes & Development, 13(15), 1899–1911.
Gupta, P. C., Ray, C. S., Sinha, D. N., & Singh, P. K. (2011). Smokeless tobacco: A major public health problem in the SEA region: A review. Indian Journal of Public Health, 55(3), 199–209.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., ... & Ashkenazi, A. (2010). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. Journal of Clinical Oncology, 28(17), 2839–2846.
Indian Council of Medical Research. (2020). National Cancer Registry Programme Report 2020. ICMR.
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018). BCL-2 family proteins: Changing partners in the dance towards death. Cell Death & Differentiation, 25(1), 65–80.
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. The EMBO Journal, 14(22), 5579–5588.
Letai, A. (2008). Diagnosing and exploiting cancer's addiction to blocks in the apoptotic pathway. Nature Reviews Cancer, 8(2), 121–132.
Li, H., Zhu, H., Xu, C. J., & Yuan, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94(4), 491–501.
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94(4), 481–490.
Micheau, O., & Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 114(2), 181–190.
Moldoveanu, T., Grace, C. R., Llambi, F., Nourse, A., Fitzgerald, P., Gehring, K., & Green, D. R. (2013). BID-induced structural changes in BAK promote apoptosis. Nature Structural & Molecular Biology, 20(5), 589–597.
Peter, M. E., & Krammer, P. H. (2003). The CD95 (APO-1/Fas) DISC and beyond. Cell Death & Differentiation, 10(1), 26–35.
Ren, D., Tu, H. C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., ... & Cheng, E. H. (2010). BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science, 330(6009), 1390–1393.
Riedl, S. J., & Salvesen, G. S. (2007). The apoptosome: Signalling platform of cell death. Nature Reviews Molecular Cell Biology, 8(5), 405–413.
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., ... & Seymour, J. F. (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374(4), 311–322.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., ... & Cristiano, R. J. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Medicine, 2(9), 985–991.
Safa, A. R. (2012). c-FLIP, a master anti-apoptotic regulator. Experimental Oncology, 34(3), 176–184.
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., ... & Elmore, S. W. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202–208.
Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer, 2(7), 489–501.
Vousden, K. H., & Lane, D. P. (2007). p53 in health and disease. Nature Reviews Molecular Cell Biology, 8(4), 275–283.
Vousden, K. H., & Prives, C. (2009). Blinded by the light: The growing complexity of p53. Cell, 137(3), 413–431.
Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., ... & Huang, D. C. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes & Development, 19(11), 1294–1305.
Youle, R. J., & Strasser, A. (2008). The BCL-2 protein family: Opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 9(1), 47–59.


